NCT07261501 An Exploratory Research on the Efficacy and Safety of Antibacterial Absorbable Dressing in Chronic Non-healing Wounds
| NCT ID | NCT07261501 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Third Hospital |
| Condition | Wound Heal |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-11-01 |
| Primary Completion | 2026-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-11-01 with a primary completion date of 2026-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Antimicrobial absorbable wound dressing is a novel polyester-based degradable dressing. Previous preclinical studies have demonstrated promising efficacy, with a 3-week wound area reduction rate of 63.53% in large animal models, outperforming foreign counterparts (49.47%), without significant adverse reactions observed during application. Toxicological risk assessment confirms acceptability, and small animal model studies show no abnormalities in toxicity or sensitization. However, current evidence lacks clinical validation, particularly regarding efficacy and safety in chronic non-healing wounds. This study integrates modern clinical evaluation methods with chronic wound staging theory to systematically investigate the effectiveness and safety of antimicrobial absorbable wound repair materials in treating chronic non-healing wounds. The research aims to identify optimal indications and provide robust evidence for its clinical efficacy and safety.
Eligibility Criteria
Inclusion Criteria: * Age : 18-80 years * Wound Type : Chronic non-healing ulcers\* with no signs of healing progression for ≥1 week * Wound Area : 1-35 cm² * Infection Status : Local infection, contamination, or colonization\*\* as classified by IWII Wound Infection Staging * Wound Phase : Late necrotic stabilization phase, granulation phase, or epithelial migration phase\*\*\* * Consent : Voluntary participation with signed informed consent Exclusion Criteria: * Severe Comorbidities : Acute myocardial infarction, heart failure, hepatitis, shock, respiratory failure, or other critical conditions requiring stabilization * Uncontrolled Diabetes : Fasting blood glucose \>15 mmol/L or HbA1c \>12% * Active Wound Hemorrhage : Bleeding precluding standard wound therapy * Critical Laboratory Values : Serum albumin \<20 g/L Hemoglobin \<60 g/L Platelet count \<50×10⁹/L * Systemic Infection : Disseminated/systemic infection requiring antibiotic therapy * Malignancy : Advanced cancer patients，Current radiotherapy/chemotherapy，Malignant (cancer-related) ulcers * Untreated Burns : Full-thickness (third-degree) burns without escharotomy * Active Autoimmune Disease : Flare-up phase of autoimmune disorders * Pregnancy/Lactation : Pregnant or breastfeeding women * Allergy : Hypersensitivity to absorbable wound repair materials or polyhexamethylene biguanide hydrochloride * Non-compliance : Inability to cooperate or psychiatric disorders * Investigator's Discretion : Any condition deemed to compromise wound healing or study adherence
Frequently Asked Questions
Who can join the NCT07261501 clinical trial?
This trial is open to participants of all sexes, aged 18 Months or older, up to 80 Years, studying Wound Heal. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07261501 currently recruiting?
Yes, NCT07261501 is actively recruiting participants. Visit ClinicalTrials.gov or contact Peking University Third Hospital to inquire about joining.
Where is the NCT07261501 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07261501 clinical trial?
NCT07261501 is sponsored by Peking University Third Hospital. The trial plans to enroll 30 participants.